Classifications: antiviral; antiretroviral agent; integrase inhibitor; Therapeutic: antiviral; antiretroviral agent
Pregnancy Category: C
400 mg tablets
Inhibits HIV-1 integrase, an enzyme required for integration of proviral DNA into the helper T-cell genome, thus preventing
formation of the HIV-1 provirus.
Inhibiting integration inhibits replication and proliferation of the HIV-1 virus.
In combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-experienced adult patients
who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents.
Treatment of na?ve HIV-1 patients; pregnancy (category C); lactation; children <16 y. Safety and efficacy in patients with
severe hepatic impairment are unknown.
Mild to moderate hepatic impairment.
Route & Dosage
Adult: PO 400 mg b.i.d.
- May be given without regard to food.
- Give before dialysis.
- Store at 1530° C (5986° F).
Adverse Effects (≥1%)Body as a Whole:
, pyrexia. CNS:
Dizziness, headache. GI:
Abdominal pain, diarrhea,
nausea, vomiting. Skin:
may increase plasma levels of raltegravir; rifampin
may decrease plasma levels of raltegravir.
3 h. Distribution:
83% protein bound. Metabolism:
In the liver. Elimination:
Stool and urine. Half-Life:
Assessment & Drug Effects
- Monitor for and report S&S of immune reconstitution syndrome (inflammatory response to residual opportunistic infections
such as MAC, CMV, PCP, or reactivation of varicella zoster).
- Lab tests: Baseline and periodic CD4+ cell count and HIV RNA viral load; periodic CBC with differential, LFTs.
- Monitor diabetics for loss of glycemic control.
Patient & Family Education
- Inform physician immediately if you plan to become or become pregnant during therapy.
- Report promptly unexplained leg pain or muscle cramping.